GLPwatch
Bydureon vs Victoza
Drug comparison
Last updated 2026-05-28 15:46 UTCBydureon (exenatide by AstraZeneca) and Victoza (liraglutide by Novo Nordisk) are both injectable medications for type 2 diabetes, but Victoza is also approved to reduce cardiovascular risk. Both are taken as shots under the skin, but Bydureon is given once a week while Victoza is taken daily. They belong to the same drug class (GLP-1 receptor agonists) but use different active ingredients.
AI summary of the sources below.
| Bydureon | Victoza | |
|---|---|---|
| Active ingredient | exenatide | liraglutide |
| Manufacturer | astrazeneca | novo-nordisk |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | type 2 diabetes | type 2 diabetes, cardiovascular risk reduction |
| Label updated | — | 2023-02-06 |